Patents
Patent Number: 7,342,110
One of the major technological advances that allowed for the characterization and use of stem cells was the development of defined monoclonal antibodies that repeatedly attached to markers on stem cells. For example, the patents covering the
original hematopoietic stem cells used monoclonal antibodies to actually identify the cell...
Inventors: Hoffee; Mary G. (Brookline, MA), Tavares; Daniel (Natick, MA), Lutz; Robert J. (Wayland, MA)
Assignee: Immunogen Inc. (Cambridge, MA)
Date of First Priority Issue: Wednesday November 5th, 2003
Patent Number: 7,396,680
The current patent covers the nucleic acid sequences for promoters. In the claims it just states "promoters" but the specification teaches that the promoters are specific to "stem cells". The examples part of the patent teaches that they are active in CD34 and CD133 cells found from cord blood.Being able to have patents on actual promoter sequences that are active...
Inventors: Shmelkov; Sergey V. (New York, NY), Rafii; Shahin (Great Neck, NY), Lin; Jun (Forest Hills, NY)
Assignee: Cornell Research Foundation, Inc. (Ithaca, NY)
Date of First Priority Issue: Friday October 31st, 2003
Patent Number: 7,220,407
Subsequent to myocardial infarction, cells of the injured myocardium release a variety of cytokines and mediators that are involved in mobilizing endogenous bone marrow stem cells and inducing their migration to the area of myocardial injury.
One cytokine released is G-CSF, which in addition to possessing hematopoietic functions also is a great mobilizer of stem cells.
In the current...
Inventors: Mehta; Jayesh (Chicago, IL), Singhal; Seema (Chicago, IL), Davidson; Charles (Winnetka, IL), Beohar; Nirat (Chicago, IL), Bonow; Robert (Glencoe, IL)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Monday October 27th, 2003
Patent Number: 7,531,510
Recruitment of various progenitor cells into injured tissue is a well known phenomena. For example, after infarct, mobilization of bone marrow stem cells into the
injured myocardium has been reported. The current patent uses G-CSF, a cytokine that stimulates
hematopoiesis and causes
mobilizationInventors: Fukuda; Keiichi (Shinjuk-ku, JP), Fujita; Jun (Shinjuku-ku, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP); Keio University (Tokyo, JP)
Date of First Priority Issue: Monday October 27th, 2003
1 Comment
Patent Number: 7,468,193
We at StemCellPatents.com have been seeing an increasing interest in "nutritional" modulation of the stem cell compartment. For example, patent #
7,338,676 teaches the use pine cone extracts for inducing differentiation of progenitor cells to dendritic cells. Patent #
6,814,961 covers the composition of blue...
Inventors: Schiffrin; Eduardo (Crissier, CH), Breuille; Denis (Epalinges, CH), Blum-Sperisen; Stephanie (Mont-Pelerin, CH), Donnet-Hughes; Anne (Saint-Legier, CH), Faure; Magali (Mollie-Margot, CH), Roessle; Claudia (Morges, CH), Turini; Marco Enrico (Epalinges, CH)
Assignee: Nestec S.A. (Vevey, CH)
Date of First Priority Issue: Thursday October 16th, 2003
Patent Number: 7,264,968
This patent covers methods of generating cells with a neuronal phenotype from cells that possess the activin receptor. Specifically, the invention provides the finding that ectodermal tissue can be induced to differentiate into neuronal tissues by inhibiting signaling of the activin receptor.
This patent has very broad reaching consequences since conceptually it covers activin receptor...
Inventors: Melton; Douglas A. (Lexington, MA), Hemmati-Brivanlou; Ali (New York, NY)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Date of First Priority Issue: Tuesday October 14th, 2003
Patent Number: 7,309,232
This patent covers a method of forming new dentin (the calcified tissue of the body of the tooth, underneath the enamel) in teeth through administration of a tissue scaffold which stem cells can grow on and regenerate the dentin. Some of the stem cells covered include stem cells from the
dental pulp. Indeed it is quite interesting...
Inventors: Rutherford; Bruce (Seattle, WA), Somogyi; Christopher (Woodinville, WA), White; Clinton (Raleigh, NC), Rabins; Erick (Seattle, WA)
Assignee: Dentigenix Inc. (Seattle, WA)
Date of First Priority Issue: Friday October 10th, 2003
Patent Number: 7,163,920
This patent discloses a novel peptide that is capable of inducing osteoblast proliferation and induction of bone synthesis. The peptide disclosed may be used as part of an implantable composition of cells and biodegradable matrices for the treatment of bone fractures.
The patent covers numerous methods of making the peptide, as well as chemical derivatives and methods of administration...
Inventors: Dhanaraj; Sridevi (Raritan, NJ), Gosiewska; Anna (Skillman, NJ), Rezania; Ali (Hillsborough, NJ), Heavner; George A. (Malvern, PA), Lin; Xuanhan (Bridgewater, NJ), Yi; Chin-Feng (Hillsborough, NJ)
Assignee: Ethicon, Inc. (Somerville, NJ)
Date of First Priority Issue: Tuesday September 30th, 2003
Patent Number: 7,510,877
The hematopoietic stem cell is the most well studied stem cell, being responsible for saving hundreds of thousands of lives through allowing the procedure of bone marrow transplant to become a reality. As far back as 1984, filings on hematopoietic stem cells can be found (
#4,714,680).The current patent has a new way of purifying hematopoietic stem cells...
Inventors: Yilmaz; Omer H. (Ann Arbor, MI), Kiel; Mark J. (Ann Arbor, MI), Morrison; Sean (Ann Arbor, MI), Iwashita; Toshihide (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Friday September 26th, 2003
Patent Number: 7,375,077
The current invention teaches the generation of connective tissue in vivo. Specifically, stem cells that have been differentiated into connective tissue cells, such as fibroblasts, are placed in a scaffold, with two other scaffolds surrounding the scaffold containing the cells. The two other scaffolds on the top and the bottom of the middle scaffold contain growth factors and...
Inventors: Mao; Jeremy Jian (Chicago, IL)
Assignee: The Board of Trustees of the University of Illinois (San Diego, CA)
Date of First Priority Issue: Friday September 19th, 2003
Patent Number: 7,494,807
This patent covers methods of isolating the megakaryocytic progenitor cells through selecting for cells that are positive for CD41, CD, and CD34 and negative for expression of CD2; CD3; CD4; CD7; CD8; CD10; CD11b; CD14; CD19; CD20; CD56; and glycophorin A. Starting materials for selection of these cells include bone marrow and mobilized peripheral blood.Platelet deficiency is a major...
Inventors: Nakorn; Thanyaphong Na (Stanford, CA), Miyamoto; Toshihiro (Fukuoka, JP), Weissman; Irving L. (Redwood City, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Date of First Priority Issue: Friday September 12th, 2003
Patent Number: 7,196,060
This patent teaches the use of a composition of matter called T-4 immune stimulating factor (TISF). This peptide was patented previously as a 50 kDa molecule in US patent # 5,616,554 as being useful for stimulation of CD4 T cell responses. The composition is derived from thymic cell lines and appears to be primarily immunostimulatory.
In the current patent the use of TISF is claimed for...
Inventors: Beardsley; Terry Raymond (Escondido, CA), Maida, III; Anthony E. (Danville, CA)
Assignee: S-Cell Biosciences, Inc. (Murrieta, CA)
Date of First Priority Issue: Wednesday September 10th, 2003
Patent Number: 7,217,294
This patent covers a method of inducing articular cartilage healing/regeneration through the implantation of acellular matrices that can be used for either delivery of cells or growth factors.
The patent is written as one independent claim covering essentially: a)the scaffold; b) a sealant that protects the scaffold from debris; c) the implantation of the scaffold; and d) the deposition of...
Inventors: Kusanagi; Akihiko (Brookline, MA), Tarrant; Laurence J. B. (Northampton, MA), Schmidt; Mary Beth (Pomfret Center, CT)
Assignee: Histogenics Corp. (Northampton, MA)
Date of First Priority Issue: Wednesday August 20th, 2003
Patent Number: 7,413,897
The liver is one of the organs that has been demonstrated to respond to stem cell therapy both in
animal models and in
clinical trials. It is known that the liver has endogenous stem cells, but also that
bone marrow stem cells can differentiate into liver cells. In fact, it is published that bone...
Inventors: Reid; Lola M. (Chapel Hill, NC), Moss; Nicholas (Carrboro, NC), Furth; Mark (Chapel Hill, NC), Ludlow; John W. (Carrboro, NC), Bruce; Andrew T. (Holly Springs, NC)
Assignee: University of North Carolina at Chapel Hill (Chapel Hill, NC); Vesta Therapeutics, Inc. (Bethesda, MD)
Date of First Priority Issue: Thursday August 14th, 2003
Patent Number: 7,417,026
Mobilization of stem cells is a very hot area these days. At face value, mobilization is important for donors of hematopoietic stem cells since it alleviates the need for performing puncture of the iliac crest of healthy people who are donating bone marrow. Currently, mobilization is performed by administering to the donor G-CSF (neupogen), which activates a cascade of enzymes and...
Inventors: Williams; David A. (Cincinnati, OH), Zheng; Yi (Cincinnati, OH)
Assignee: Children's Hospital Medical Center (Cincinnati, OH)
Date of First Priority Issue: Wednesday August 13th, 2003
Patent Number: 7,314,959
One of the important areas of drug development is protecting stem cells and healthy tissue from the damaging effects of cytotoxic chemotherapy and radiation therapy. In fact, a "stem cell therapy" that has become a multi-billion dollar product is the use of G-CSF to stimulate hematopoietic recovery after cancer therapy or bone marrow transplantation. In fact, numerous patents have been filed for...
Inventors: Fahl; William E. (Madison, WI), Peebles; Daniel D. (Fond du Lac, WI), Copp; Richard C. (Oregon, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Date of First Priority Issue: Thursday August 7th, 2003
Patent Number: 7,349,740
The positive effects of stem cells in cardiac conditions is supported by many clinical trials. Efficacy has been demonstrated by both intracoronary administration, as well as intravenous administration of bone marrow and mesenchymal stem cells, respectively.In this patent, Medronics was granted some pretty far-reaching claims. This is a representative claim "A method comprising...
Inventors: Soykan; Orhan (Shoreview, MN), Maura; Donovan G. (St. Paul, MN)
Assignee: Medtronic, Inc. (Minneapolis, MN)
Date of First Priority Issue: Monday July 28th, 2003
Patent Number: 7,326,571
Numerous patents have been filed on de-cellularized tissues for use as matrices. For example, patent #
6,696,074 teaches that various fetal tissues may be de-cellularized and used as scaffolds. Such scaffolds may be seeded with various differentiated or stem cells, such as
Inventors: Freyman; Toby (Watertown, MA)
Assignee: Boston Scientific Scimed, Inc. (Maple Grove, MN)
Stem cell therapy for cardiac indications may take a variety of forms. One of the easiest is
. This would require the stem cells to selectively home into damaged tissue. It is known that various inflammatory agents such as